NLM Digital Collections

Search

Start Over Subjects Patient Selection ✖Remove constraint Subjects: Patient Selection Titles Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment ✖Remove constraint Titles: Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment Publication Year 2020 ✖Remove constraint Publication Year: 2020

Refine by:

more »

  • Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment1